Previous 10 | Next 10 |
2023-08-12 07:30:00 ET CRISPR Therapeutics (NASDAQ: CRSP) is one of the most innovative biotechs out there, and that means there's no shortage of reasons to consider buying its stock. But much like its peers, it's a high-risk investment until it gets its first medicine out the door ...
2023-08-11 09:45:00 ET With shares of CRISPR Therapeutics (NASDAQ: CRSP) down by 40% over the last 12 months, some investors might rightly wonder if this young biotech has lost its way. But the market has been hard on biotechnology stocks in general of late. And now, thanks to a...
2023-08-10 14:50:27 ET Summary Vertex Pharmaceuticals Incorporated is performing well in the Cystic Fibrosis market with its drug Trikafta, leading to an increase in full-year 2023 guidance. The company has two expansion opportunities in place to counter the potential entry of gen...
2023-08-09 09:30:00 ET One of the good things about equity markets is that there are great stocks to be had at almost any price. Not all companies whose shares are worth buying are trading for hundreds or thousands of dollars apiece. For less than $100, investors can buy quality stocks that...
2023-08-08 15:46:11 ET More on CRISPR Therapeutics Vertex And CRISPR Therapeutics - Partners On Exa-cel - But Unequally Valued Crispr Therapeutics: Biotech To Watch With Regulatory Approvals Of Exa-Cel On Deck Crispr Therapeutics Has Value Creation Potential ...
2023-08-07 16:55:51 ET CRISPR Therapeutics press release ( NASDAQ: CRSP ): Q2 GAAP EPS of -$0.98 beats by $1.12 . Revenue of $70M. Total collaboration revenue was $70.0 million for the quarter ended June 30, 2023. Collaboration revenue for the second quarter of 202...
-FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT); Priority Review for SCD and Standard Review for TDT- -PDUFA target action date of December 8, 2023, for SCD and ...
2023-08-06 08:01:00 ET The second week of August promises to be an eventful one for investors as a slew of major companies is set to report quarterly results. Among the headliners, Disney ( NYSE: DIS ) is prehaps the most well-known company due to report. The schedule also incl...
2023-07-31 05:30:00 ET Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) both are approaching a crucial moment in their stories. The biotech companies are awaiting regulatory decisions for exa-cel, their potential blockbuster treatment for blood di...
2023-07-28 17:01:08 ET Summary Vertex is a $90bn market cap Pharma giant with a monopolistic control of the cystic fibrosis industry. CRISPR Therapeutics is an obscure - to some - Swiss Pharma focused on gene therapy, leveraging Nobel Prize winning technology. The two companie...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website: